To accomodate accelerating research activity at Clinical Sensors, the company has acquired a new laboratory space at the First Flight Venture Center in Research Triangle Park, NC.
The new labs quadruple the total available bench space for Clinical Sensors, and provide ample room for the growing research team. Clinical Sensors has equipped the space with a suite of state-of-the-art tools and equipment for further developing its sensor technologies.
Dr. Jon McDunn has joined Clinical Sensors as Director of Medical Device Initiatives. Dr. McDunn is an expert in the biology of inflammation, has over 20-years experience in clinical research, and has made significant contributions to the scientific understanding of sepsis pathology. Dr. McDunn brings commercialization and product development experience to Clinical Sensors, having led teams at Incyte Genomics and Metabolon to commercialize medical devices and research services.
Clinical Sensors has been awarded $1.3 million from the National Institutes of Health / National Institute of Diabetes and Digestive and Kidney Diseases through a Phase II SBIR grant, "Improving the Host Response to Implantable Glucose Sensors via Nitric Oxide Release".
Through this project, Clinical Sensors is developing coatings that improve the accuracy and longevity of implanted continuous glucose monitoring (CGM) devices. CGM sensors are being increasingly used to improve glycemic management for diabetics, and our coating has the potential to improve their accuracy and lifetime, and reduce the number of finger stick calibrations required for patients.
Dr. Wesley Storm, Ph.D. has joined Clinical Sensors as Senior Scientist to lead execution of the technical and research objectives of the company. Dr. Storm is a graduate of the Schoenfisch lab and brings expertise in nitric oxide and membrane chemistry, as well as electrochemistry and sensor design.
With Dr. Storm's hire, Clinical Sensors has moved into laboratory space at First Flight Venture Center to further research and development of the company's NO sensor technology.
Clinical Sensors has received $600,000 from the National Institutes of Health / National Institute of Allergy and Infectious Diseases through a two-year Phase 1 STTR research program titled "Nitric Oxide Microfluidic Sensor". Through this program, Clinical Sensors will develop an accurate and manufacturable nitric oxide (NO) sensor that enables measurement of NO levels from small volumes of blood with minimal sample processing.